Advantagene reaches SPA agreement with FDA for ProstAtak Phase 3 trial to avoid prostate cancer recurrence Advantagene, Inc Click here ., a Massachusetts-based biopharmaceutical company, announced today that it reached an agreement with the U.S. The trial is expected to accrue 711 patients starting mid-2011 with definitive outcomes anticipated by 2015. The randomized research will evaluate ProstAtak’s capability to prevent prostate malignancy recurrence. If successful, it might yield the first medication product for diagnosed newly, localized prostate tumor. Prostate cancer may be the second most common reason behind death in American guys.
‘Scientists in Japan and Wisconsin used four genes to ‘reprogram’ ordinary adult individual cells, creating ‘induced pluripotent stem cells’ . James Thomson, mind of the Wisconsin team and the founder of human being embryonic stem cell study, says these cells ‘match the defining criteria’ for pluripotent human embryonic stem cells, ‘with the significant exception that the iPS cells are not produced from embryos.’ Related StoriesNYSCF, CBR collaborate to customize creation of high-quality stem cell linesTUM experts uncover signaling pathways that play essential role in self-renewal of bloodstream stem cellsSCT, Thermo Fisher Scientific collaborate to progress advancement of cardiac disease versions’Thus the goal sought for years through failed tries at individual cloning – the creation of ‘pluripotent’ stem cells that are an exact genetic match to a patient – has been brought within reach by an ethical procedure.